Emerging Company In An Emerging Market: Shenogen Aims To Combine Modern Science And TCMs
This article was originally published in PharmAsia News
Executive Summary
Shenogen is a startup aimed at discovery and development of small molecule and biologic drugs targeted at a novel estrogen receptor (ER) variant discovered and characterized by the company. Its leading compound SNG-162 (icaritin) is in Phase II clinical trials in China.